Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,248 across all filing types
Latest filing 2020-02-01 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is a notice regarding the transfer of unclaimed interim dividends and corresponding equity shares to the Investor Education and Protection Fund (IEPF) Authority for the financial year 2012-13. It references compliance with SEBI regulations and the Companies Act, 2013, and details the process and deadlines for shareholders to claim their dividends before transfer. The document includes a newspaper advertisement and a formal company notice but does not contain financial statements, audit results, or detailed financial performance data. It is an official announcement related to shareholder dividend matters and regulatory compliance rather than a financial report or earnings release. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2020-02-01 English
Updates
Regulatory Filings Classification · 95% confidence The document is a notice of a Board Meeting scheduled for February 11, 2020, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended December 31, 2019. It includes a newspaper advertisement of the notice and references the publication of the financial results in newspapers. The document does not contain the financial results themselves but is an announcement related to the upcoming approval and publication of those results. Therefore, it is not the financial report (like an Interim/Quarterly Report) but rather a Regulatory Filing (RNS) announcing the meeting and related financial results publication.
2020-02-01 English
Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby enclose copies of the newspaper notice published in The Free Press Journal ....
Regulatory Filings
2020-02-01 English
Please find enclosed herewith the copy of the newspaper advertisement of notice of Board Meeting of the Company will be held on Tuesday, February 11, 2020 at the registered office of the ....
Regulatory Filings
2020-02-01 English
Board Meeting — Financial Results/Other business matters
Regulatory Filings Classification · 90% confidence The document is extremely short (383 characters) and contains only address and listing department information for stock exchanges without any substantive content or financial data. There is no indication of a report, announcement, or detailed filing. It appears to be a brief communication or header without meaningful filing content. Given the lack of any specific report or announcement, the best fit is Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit elsewhere.
2020-01-31 English
BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2020 ,inter alia, to consider and approve the Un-audited Standalone ....
Regulatory Filings
2020-01-31 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.